SGRY
Surgery Partners, Inc. Health Care Services-General Medical & Surgical Hospitals, NEC Russell 3000
$23.21Close
$3.0BMarket cap
$11.49 – $23.3652-week range
Nov 9, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 91 · stronger than 91% of stocks over 12 months
- Near its high 1% below its 52-week high
- Accumulation up-day volume 2.4× down-day volume over 50 sessions
Cautions
- Extended 14.3 ATR above its 50-day average
- Results soon Nov 9, 2026, in 8 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
1%
1wk
up 47.4%
price change
1mo
up 67.3%
price change
12-month return
up 5%
market up 11% ·
its own down 9%
F-score
—
— Not assessed
Altman Z″
0.71
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.8×
price / book
Earnings yield
up 6.0%
EBIT / enterprise value
Cheaper than
76%
of the market · cheap
Revenue growth
up 6%
year on year
EPS growth
—
latest quarter
Sales growth
up 3%
latest quarter · -2 pts
ROE
down 4%
return on equity
Free cash margin
up 6%
$195.6M FCF
D/E
2.16
long-term debt / equity
Net debt / EBITDA
6.1×
Interest cover
—EBIT / interest
Trade setup
ATR%
3.7%
$0.86 a day · 2×ATR $21.48
RS
91 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
2.38
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Heavily indebted Net debt is 6.1 times EBITDA — roughly 6 years of earnings before interest, tax and depreciation to repay borrowings in full.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026-3% vs market2 sessions after results
Financials
- Net -2%
- Free cash 6%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9B | $2.2B | $2.5B | $2.7B | $3.1B | $3.3B |
| Operating income | $183.0M | $302.2M | $345.2M | $328.0M | $348.8M | $389.5M |
| Net income | -$116.1M | -$70.9M | -$54.6M | -$11.9M | -$168.1M | -$77.9M |
| Net margin | -6% | -3% | -2% | -0% | -5% | -2% |
| Earnings per share | -$2.38 | -$0.98 | -$0.59 | -$0.09 | -$1.33 | -$0.61 |
| Free cash flow | $204.0M | $29.5M | $78.2M | $205.0M | $209.7M | $195.6M |
| Free cash margin | 11% | 1% | 3% | 7% | 7% | 6% |
| Cash | $317.9M | $389.9M | $282.9M | $195.9M | $269.5M | $239.9M |
| Long-term debt | $2.9B | $2.9B | $2.6B | $2.8B | $3.4B | $3.7B |
| Shareholders' equity | $115.6M | $1.1B | $2.0B | $2.0B | $1.8B | $1.7B |
| Shares outstanding | 50.46m | 89.33m | 125.96m | 126.59m | 127.11m | 129.32m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 7, 2025 | Annual ↗ | Dec 31, 2024 | 66d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 26, 2024 | Annual ↗ | Dec 31, 2023 | 57d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 26, 2026 | Material agreement · Regulation FD ↗ |
| Sep 17, 2026 | Acquisition or disposal ↗ |
| Aug 10, 2026 | Results ↗ |
| Jul 24, 2026 | Material agreement · Regulation FD ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Mar 2, 2026 | Results · Regulation FD ↗ |
| Dec 16, 2025 | Material agreement · New obligation ↗ |
| Dec 12, 2025 | Other events ↗ |
| Dec 11, 2025 | Regulation FD ↗ |
| Nov 12, 2025 | Director or officer change ↗ |
| Nov 10, 2025 | Results ↗ |